Table 4.

First-line endocrine therapy for metastatic breast cancer

	CHEK2		Non-CHEK2		P
	N	%	N	%
Number of patients	36		32
Type of endocrine therapy
Tamoxifen	26	72	17	53	0.23
Aromatase inhibitor	7	19	9	28
Other	3	8	6	19
Best response
Objective response	5	14	6	19	0.82
Stable disease	18	52	14	45
Progressive disease	12	34	11	36
Unknown	1	–	1	–
Progression-free survival
6 months	20	56	19	59	0.12
12 months	14	39	13	41
24 months	3	8	6	19
HR univariatea	1.50	0.90–2.49
Overall survival
6 months	36	100	31	97	0.12
12 months	34	94	28	88
24 months	26	78	26	81
HR univariatea	1.51	0.89–2.57

^aNone of the added variables (age at diagnosis, ER status, adjuvant chemotherapy, metachronous contralateral breast cancer, type of first metastases, distant disease-free interval) had >10 % influence on the hazard ratio (HR); therefore, no multivariate HR was calculated